BETA DRUGS LIMITED DCF Valuation
BETA · Healthcare · Current price ₹2,229.1
BETA DRUGS LIMITED intrinsic-value estimate
Our intrinsic-value model estimates BETA DRUGS LIMITED is worth ₹317 per share, based on 19% ROE fading to 13% over ~10 yrs, on ₹241 book. Rather than a raw DCF — which is highly sensitive to fragile cash-flow forecasts — we use a residual-income (excess-return) model: a company is worth its book value plus the present value of the returns it earns ABOVE its cost of equity. A narrow economic moat sets how long that edge is assumed to last.
Try your own assumptions
Prefer a classic discounted-cash-flow view? Open the DCF calculator below — it pre-fills BETA DRUGS LIMITED's real free cash flow, net debt and share count so you can model your own growth and discount-rate scenario in seconds.
More on BETA DRUGS LIMITED
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.